Results 31 to 40 of about 38,769 (305)

Sodium–Glucose Cotransporter 2 Inhibitors Work as a “Regulator” of Autophagic Activity in Overnutrition Diseases

Frontiers in Pharmacology, 2021
Several large clinical trials have shown renal and cardioprotective effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors in diabetes patients, and the protective mechanisms need to be elucidated.
Kazuhiko Fukushima, Shinji Kitamura, Kenji Tsuji, Jun Wada   +3 more
doaj   +1 more source

An emerging protagonist: Sodium Glucose Co-transporters (SGLTs) as a burgeoning target for the treatment of diabetes mellitus

, 2012
Contemporary therapies to rationalize the hyperglycaemia in type 2 diabetes mellitus (T2DM) generally involve insulin-dependent mechanisms and lose their effectiveness as pancreatic b-cell function decreases to a greater extent. The kidney emerges out as
Manju Sharma, Vikas Kumar, Danish Ahmed, Vikas Kumar, Pankaj S Yadav   +4 more
core   +1 more source

Flozins in Reducing Cardiovascular and Metabolic Risk: A Literature Review

Quality in Sport
Introduction Cardiovascular diseases (CVD) are a significant worldwide health issue, impacting millions of patients and being the primary cause of global illness and death.
Daria Sieniawska, Julia Sieniawska, Patrycja Proszowska   +2 more
doaj   +1 more source

The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study

Diabetes & Vascular Disease Research, 2022
Background The association of the use of sodium-glucose cotransporter 2 (SGLT2) inhibitor and incident dementia remains unclear. This study aimed to evaluate the risk of incident dementia with the use of SGLT2 inhibitor.
Wun-Zhih Siao, Tsung-Kun Lin, Jing-Yang Huang, Chin-Feng Tsai, Gwo-Ping Jong   +4 more
doaj   +1 more source

A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review

Kidney & Blood Pressure Research, 2023
Background: Sodium-glucose cotransport protein 2 (SGLT2) inhibitors, a new type of glucose-lowering drug, have been well proved in several clinical studies for their glucose-lowering and nephroprotective effects, and the nephroprotective effects include ...
Jinfang Song, Xia Li, Jiang Ni
doaj   +1 more source

Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis

Scientific Reports, 2021
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown impressive effects in reducing major vascular events in several randomized controlled trials (RCTs).
Wen-Hsuan Tsai, Shih-Ming Chuang, Sung-Chen Liu, Chun-Chuan Lee, Ming-Nan Chien, Ching-Hsiang Leung, Shu-Jung Liu, Hong-Mou Shih   +7 more
doaj   +1 more source

BDNF Levels and Cognitive Function in Patients with Type 2 Diabetes Treated with SGLT2 Inhibitors [PDF]

Objective: As cognitive impairment becoming more widely recognized as a complication of type 2 diabetes mellitus (T2DM), it is discussed in the literature that antihyperglycemic treatment may also improve cognitive functions.
Esra ÇALIŞICI, Betül SÜMBÜL ŞEKERCİ, Abdüsselam ŞEKERCİ, Şeymanur DEMİRHAN   +3 more
core   +1 more source

Additional file 1 of Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus

, 2022
Additional file 1: Figure S1. Study design. Figure S2. Risk of cardiovascular event among SGLT2 Inhibitors (continuous prescription group). Figure S3. Risk of cardiovascular event among SGLT2 inhibitors (induction period ≥ 90 days). Figure S4.
Norifumi Takeda (422775), Satoshi Matsuoka (203621), Hidetaka Itoh (12566643), Yuta Suzuki (695228), Koichi Node (384063), Atsuhiko Matsunaga (531384), Hidehiro Kaneko (12566640), Nobuaki Michihata (9235584), Kentaro Kamiya (1874644), Hiroyuki Morita (505542), Junya Ako (685191), Issei Komuro (48691), Hideo Yasunaga (49205), Akira Okada (2716030), Katsuhito Fujiu (559488), Taisuke Jo (673195)   +15 more
core   +1 more source

CARDIOPROTECTIVE PROPERTIES OF SGLT2-INHIBITORS [PDF]

Archiv Euromedica
Due to its high mortality rate, heart failure (HF) presents a substantial worldwide health burden that calls for efficient treatment approaches. Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) have become essential treatments for heart failure in all left ventricular ejection fraction (LVEF) levels.
Karol Wielgus, Maria Pawłowska, Piotr Bator, Adrian Bobrzyk, Angelika Wawryszuk, Weronika Kamińska, Karol Magiera, Jan Ramian, Grzegorz Łyko, Maria Antos   +9 more
openaire   +1 more source

Canagliflozin Alleviates Diabetic Glomerular Endothelial Injury via Melibiose in a Microbiota‐Dependent Manner

Advanced Science, EarlyView.
Canagliflozin treatment reshapes the gut microbiota in DKD and elevates levels of melibiose, a metabolite derived from Roseburia intestinalis. Melibiose directly binds to and enhances the enzymatic activity of glyoxalase 1, leading to decreased methylglyoxal accumulation.
Wei Zhang, Yi Song, Changkun Li, Yuanyuan Luo, Mingwei Shao, Feng Guo, Fangyi Wei, Xunjie Fan, Wenwen Guo, Fengmei Xu, Yanhong Sang, Dongming Zhang, Yanhong Zhou, Lianwei Wang, Zhiqiang Kang, Yingjun Yang, Chunhua Song, Yanxia Liu, Xiaojun Ma, Jiao Wang, Chong Li, Shengnan Ma, Lin Zhao, Zhi Qin, Guolan Xing, Qiubo Zhao, Jun Li, Shumin Song, Dan Zhao, Ting Huang, Qingzhu Wang, Yanyan Zhao, Guijun Qin   +32 more
wiley   +1 more source